Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries.

Autor: Lauppe R; Quantify Research, Stockholm, Sweden., Liseth Hansen J; Quantify Research, Stockholm, Sweden.; Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway., Fornwall A; Quantify Research, Stockholm, Sweden., Johansson K; Pfizer AB, Stockholm, Sweden., Rozenbaum MH; Pfizer, Inc., Capelle a/d IJssel, The Netherlands., Strand AM; Pfizer Denmark ApS, Ballerup, Denmark., Väkeväinen M; Pfizer Oy, Helsinki, Finland., Kuusisto J; Department of Medicine and Clinical Research, Kuopio University Hospital and University of Eastern Finland, Kuopio, Finland., Gude E; Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway., Smith JG; Department of Cardiology, Wallenberg Center for Molecular Medicine and Lund University Diabetes Center, Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden.; The Wallenberg Laboratory/Department of Molecular and Clinical Medicine, Institute of Medicine, Gothenburg University and Sahlgrenska University Hospital, Gothenburg, Sweden., Gustafsson F; Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
Jazyk: angličtina
Zdroj: ESC heart failure [ESC Heart Fail] 2022 Aug; Vol. 9 (4), pp. 2528-2537. Date of Electronic Publication: 2022 May 12.
DOI: 10.1002/ehf2.13961
Abstrakt: Aims: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive condition caused by deposition of transthyretin amyloid fibrils in the heart and is associated with poor quality of life and a shortened lifespan. This study aimed to describe the prevalence, clinical characteristics, and mortality of patients with ATTR-CM, using multiple national health registers in Denmark, Finland, Norway, and Sweden.
Methods and Results: Transthyretin amyloid cardiomyopathy patients were identified during 2008-2018 using a combination of diagnosis codes for amyloidosis and heart disease and were matched to patients with non-ATTR heart failure (HF). An identical study design was used in each country to facilitate comparison and aggregation of results. A total of 1930 ATTR-CM patients were identified from national health registers in the four countries. In 2018, prevalence of ATTR-CM per 100 000 inhabitants ranged from 1.4 in Denmark to 5.0 in Sweden; a steep increase over time was observed in Sweden and Norway. Median survival from diagnosis was 30 months for ATTR-CM patients and 67 months for matched HF patients. Survival was significantly lower for female than for male ATTR-CM patients (median survival: 22 and 36 months), while no significant difference was observed in the HF cohort.
Conclusions: This study provides the first nationwide estimates of the prevalence, clinical characteristics, and mortality of patients with ATTR-CM, using identical study design across several countries. Findings corroborate previous case series showing high mortality in ATTR-CM, two-fold higher than for other HF patients and higher in women than men, highlighting the need for more precise and early diagnosis to reduce the disease burden.
(© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
Databáze: MEDLINE
Externí odkaz: